Skip to main content
Erschienen in: Clinical and Translational Oncology 10/2013

01.10.2013 | Educational Series - Red Series

Consensus on the regional lymph nodes irradiation in breast cancer

verfasst von: E. Bayo, I. Herruzo, M. Arenas, M. Algara

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Standard locoregional treatment of early-stage breast cancer currently consists of the conservative surgery and sentinel lymph node biopsy. In the event of positive sentinel node biopsy, an axillary level I–II lymphadenectomy should be carried out. However, recent publications have increasingly supported a tendency not to apply the surgical lymphadenectomy, but simultaneously, it has been developed a new role of regional radiotherapy, even if there is only 1–3 axillary lymph nodes involved. Given these new trends, radiation oncologists are facing the dilemma with regard to deciding about regional irradiation of breast cancer. For such purpose, The Spanish Group of Breast Cancer Radiation Oncology (GEORM as per its Spanish acronym) decided to reach a consensus to issue the respective guidelines for such types of cases. GEORM Managing Commission, gathering 13 members of different Spanish regional communities, issued a questionnaire including different clinical situations. These questions were set as key questions seeking responses, which were answered by 66 % out of the 75 members of the group. Following the response, the guidelines were drafted based on the replies to the mentioned questionnaire. All the respective issues were discussed by means of a virtual platform. In this article, we show the levels of consensus for different clinical situations, depending on the number of nodes involved and the type of surgical procedure performed on the axillary lymph nodes. The ongoing evolution of the oncological treatments obliges the radiation oncologists to take decisions without any existing clarifying evidence, and therefore, the consensus is necessary, which can assist in the decision-making process by the practitioners in such kinds of clinical situations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kiluk JV, Ly QP, Meade T, Ramos D, Reintgen DS, Dessureault S, et al. Axillary recurrence following negative sentinel node biopsy for invasive breast cancer: long term follow-up. Ann Surg Oncol. 2011;18:S339–3442.PubMedCrossRef Kiluk JV, Ly QP, Meade T, Ramos D, Reintgen DS, Dessureault S, et al. Axillary recurrence following negative sentinel node biopsy for invasive breast cancer: long term follow-up. Ann Surg Oncol. 2011;18:S339–3442.PubMedCrossRef
2.
Zurück zum Zitat Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMed Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMed
3.
Zurück zum Zitat Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.PubMedCrossRef Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.PubMedCrossRef
4.
Zurück zum Zitat Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001.PubMedCrossRef Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001.PubMedCrossRef
5.
Zurück zum Zitat Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (apbi) after breast-conserving surgery: recommendations of the groupe européen de curiethérapie-european society for therapeutic radiology and oncology (GEC-ESTRO) Breast Cancer Working Group based on clinical evidence. Radiother Oncol. 2010;94(3):264–73.PubMedCrossRef Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (apbi) after breast-conserving surgery: recommendations of the groupe européen de curiethérapie-european society for therapeutic radiology and oncology (GEC-ESTRO) Breast Cancer Working Group based on clinical evidence. Radiother Oncol. 2010;94(3):264–73.PubMedCrossRef
6.
Zurück zum Zitat Liyi X, Higginson DS, Marks LB. Elective regional nodal Irradiation in patients with early-stage breast cancer. Semin Radiat Oncol. 2011;21(1):66–78.CrossRef Liyi X, Higginson DS, Marks LB. Elective regional nodal Irradiation in patients with early-stage breast cancer. Semin Radiat Oncol. 2011;21(1):66–78.CrossRef
7.
Zurück zum Zitat Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in International consensus reports in a subgroup analysis of the DBCG 82b and c randomized trials. Radiother Oncol. 2007;82:247–53.PubMedCrossRef Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in International consensus reports in a subgroup analysis of the DBCG 82b and c randomized trials. Radiother Oncol. 2007;82:247–53.PubMedCrossRef
8.
Zurück zum Zitat Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomized Trial. J Natl Cancer Inst. 2005;97:116–26.PubMedCrossRef Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomized Trial. J Natl Cancer Inst. 2005;97:116–26.PubMedCrossRef
9.
Zurück zum Zitat Whelan TJ, Olivotto I, Ackerman I, Chapman JW, Chua B, Nabid A, et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol. 2011; 29:80s suppl 15; abstr LBA1003. Whelan TJ, Olivotto I, Ackerman I, Chapman JW, Chua B, Nabid A, et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol. 2011; 29:80s suppl 15; abstr LBA1003.
10.
Zurück zum Zitat Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, et al. Clinical cancer advances 2011: report on progress against cáncer from the American Society of Clinical Oncology. J Clin Oncol. 2012;30(1):88–109.PubMedCrossRef Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, et al. Clinical cancer advances 2011: report on progress against cáncer from the American Society of Clinical Oncology. J Clin Oncol. 2012;30(1):88–109.PubMedCrossRef
11.
Zurück zum Zitat Wely BJ, Teerenstra S, Schinagi DAX, Aufenacker TJ, Wilt JHW, Stronne JA. Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biobsy. Br J Surg. 2011;98:326–33.PubMedCrossRef Wely BJ, Teerenstra S, Schinagi DAX, Aufenacker TJ, Wilt JHW, Stronne JA. Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biobsy. Br J Surg. 2011;98:326–33.PubMedCrossRef
12.
Zurück zum Zitat Setton J, Cody H, Tan L, Morrow M, Hudis C, Catalano J, et al. Radiation field design and regional control in sentinel lymph node-positive cancer patients with omision of axillary dissection. Cancer. 2011; Aug 31. doi:10.1002/cncr.26504. Setton J, Cody H, Tan L, Morrow M, Hudis C, Catalano J, et al. Radiation field design and regional control in sentinel lymph node-positive cancer patients with omision of axillary dissection. Cancer. 2011; Aug 31. doi:10.​1002/​cncr.​26504.
13.
Zurück zum Zitat Veronesi U, Orecchia R, Zurrida S, Galimberti V, Luini A, Veronesi P, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005;16:383–8.PubMedCrossRef Veronesi U, Orecchia R, Zurrida S, Galimberti V, Luini A, Veronesi P, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005;16:383–8.PubMedCrossRef
14.
Zurück zum Zitat Martelli G, Boracchi P, De Palo M, Pilotti S, Oriana S, Zucali R, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer. Ann Surg. 2005;242(1):1–6.PubMedCrossRef Martelli G, Boracchi P, De Palo M, Pilotti S, Oriana S, Zucali R, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer. Ann Surg. 2005;242(1):1–6.PubMedCrossRef
15.
Zurück zum Zitat Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph node who do not undergo completion axillary dissection. Cancer. 2007;110(4):723–30.PubMedCrossRef Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph node who do not undergo completion axillary dissection. Cancer. 2007;110(4):723–30.PubMedCrossRef
16.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(18):2946–53.PubMedCrossRef Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(18):2946–53.PubMedCrossRef
17.
Zurück zum Zitat Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cáncer. Ten years results of a randomized controlled study. Ann Surg. 2010;251(4):595–600.PubMedCrossRef Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cáncer. Ten years results of a randomized controlled study. Ann Surg. 2010;251(4):595–600.PubMedCrossRef
18.
Zurück zum Zitat Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, et al. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: a practice-changing trial. Ann Surg Oncol. 2011;18(9):2407–12.PubMedCrossRef Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, et al. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: a practice-changing trial. Ann Surg Oncol. 2011;18(9):2407–12.PubMedCrossRef
19.
Zurück zum Zitat Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. A randomized clinical trial. JAMA. 2011;305(6):569–75.PubMedCrossRef Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. A randomized clinical trial. JAMA. 2011;305(6):569–75.PubMedCrossRef
20.
Zurück zum Zitat Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without dissection in patients with sentinel lymph node metastases. Ann Surg. 2010;252:426–33.PubMed Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without dissection in patients with sentinel lymph node metastases. Ann Surg. 2010;252:426–33.PubMed
22.
Zurück zum Zitat Van Deurzen CHM, Van Hillegersberg R, Hobbelink MGG, Seldenrijk CA, Koelemij R, Van Diest PJ. Predictive value of tumor load in breast cancer sentinel lymph nodes for second echelon lymph node metastases. Cell Oncol. 2007;29(6):497–505.PubMed Van Deurzen CHM, Van Hillegersberg R, Hobbelink MGG, Seldenrijk CA, Koelemij R, Van Diest PJ. Predictive value of tumor load in breast cancer sentinel lymph nodes for second echelon lymph node metastases. Cell Oncol. 2007;29(6):497–505.PubMed
23.
Zurück zum Zitat Barbosa EM, Francisco ARF, Araujo Neto JT, Alves EMF, Tavares MGM, Góes JCS. Clinicopathological predictor factors of axillary involvement in patients with metastatic breast cancer in the sentinel lymph node. Revista Brasileira de Ginecologia e Obstetricia. 2010;32(3):144–9.PubMedCrossRef Barbosa EM, Francisco ARF, Araujo Neto JT, Alves EMF, Tavares MGM, Góes JCS. Clinicopathological predictor factors of axillary involvement in patients with metastatic breast cancer in the sentinel lymph node. Revista Brasileira de Ginecologia e Obstetricia. 2010;32(3):144–9.PubMedCrossRef
24.
Zurück zum Zitat Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Nayeemuddin KM, et al. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008;15(12):3369–77.PubMedCrossRef Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Nayeemuddin KM, et al. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008;15(12):3369–77.PubMedCrossRef
25.
Zurück zum Zitat Viale G, Maiorano E, Pruneri G, Mastropasqua MG, Valentini S, Galimberti V, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241(2):319–25.PubMedCrossRef Viale G, Maiorano E, Pruneri G, Mastropasqua MG, Valentini S, Galimberti V, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241(2):319–25.PubMedCrossRef
26.
Zurück zum Zitat Jinno H, Sakata M, Asaga S, Wada M, Shimada T, Kitagawa Y, et al. Predictors to assess non sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis. Breast J. 2008;14(6):551–5.PubMedCrossRef Jinno H, Sakata M, Asaga S, Wada M, Shimada T, Kitagawa Y, et al. Predictors to assess non sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis. Breast J. 2008;14(6):551–5.PubMedCrossRef
27.
Zurück zum Zitat Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, et al. One step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007;13(16):4807–16.PubMedCrossRef Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, et al. One step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007;13(16):4807–16.PubMedCrossRef
28.
Zurück zum Zitat Pepels MJ, de Boer M, Bult P, van Dijck JA, van Deurzen CH, Menke-Pluymers MB, et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells. Ann Surg. 2012;255(1):116–21.PubMedCrossRef Pepels MJ, de Boer M, Bult P, van Dijck JA, van Deurzen CH, Menke-Pluymers MB, et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells. Ann Surg. 2012;255(1):116–21.PubMedCrossRef
29.
Zurück zum Zitat Lupe K, Truong PT, Alexander C, Speers C, Tydesley S. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection. Int J Radiat Oncol Biol Phys. 2011;81(5):681–6.CrossRef Lupe K, Truong PT, Alexander C, Speers C, Tydesley S. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection. Int J Radiat Oncol Biol Phys. 2011;81(5):681–6.CrossRef
30.
Zurück zum Zitat Gobardhan PD, Elias SG, Madsen EV, van Wely B, van den Wildenberg F, Theunissen EB, et al. Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study. Ann Surg Oncol. 2011;18(6):1657–64.PubMedCrossRef Gobardhan PD, Elias SG, Madsen EV, van Wely B, van den Wildenberg F, Theunissen EB, et al. Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study. Ann Surg Oncol. 2011;18(6):1657–64.PubMedCrossRef
31.
Zurück zum Zitat Toussaint A, Nogaret JM, Veys I, Hertens D, Noterman D, De Neubourg F, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph biopsy or containing micrometastases and without further lymphadenectomy monocentric review of 8 years and 481 cases. Breast. 2011;17(4):337–442.CrossRef Toussaint A, Nogaret JM, Veys I, Hertens D, Noterman D, De Neubourg F, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph biopsy or containing micrometastases and without further lymphadenectomy monocentric review of 8 years and 481 cases. Breast. 2011;17(4):337–442.CrossRef
32.
Zurück zum Zitat Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129(3):675–89.PubMedCrossRef Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129(3):675–89.PubMedCrossRef
34.
Zurück zum Zitat Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS 3rd. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462–8.PubMedCrossRef Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS 3rd. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462–8.PubMedCrossRef
35.
Zurück zum Zitat Houvenaeghel G, Bannier M, Nos C, Giard S, Mignotte H, Jacquemier J, et al. Non sentinel node involvement prediction for sentinel node micrometastases in breast cancer: nomogram validation and comparison with other models. Breast. 2012;21(2):204–9.PubMedCrossRef Houvenaeghel G, Bannier M, Nos C, Giard S, Mignotte H, Jacquemier J, et al. Non sentinel node involvement prediction for sentinel node micrometastases in breast cancer: nomogram validation and comparison with other models. Breast. 2012;21(2):204–9.PubMedCrossRef
36.
Zurück zum Zitat Degnim AC, Reynolds C, Pantvaidya G, Zakaria S, Hoskin T, Barnes S, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predicting nomogram. Am J Surg. 2005;190:543–50.PubMedCrossRef Degnim AC, Reynolds C, Pantvaidya G, Zakaria S, Hoskin T, Barnes S, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predicting nomogram. Am J Surg. 2005;190:543–50.PubMedCrossRef
37.
Zurück zum Zitat Scow JS, Degnim AC, Hoskin TL, Reynolds C, Boughey JC. Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. Cancer. 2009;115(18):4064–70.PubMedCrossRef Scow JS, Degnim AC, Hoskin TL, Reynolds C, Boughey JC. Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. Cancer. 2009;115(18):4064–70.PubMedCrossRef
38.
Zurück zum Zitat Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.PubMedCrossRef Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.PubMedCrossRef
39.
Zurück zum Zitat Coufal O, Pavlik T, Fabian P, Bori R, Boross G, Sejben I, et al. Predicting non-sentinel lymph node status after positive sentinel biopsy in breast cancer: what model performs the best in a Czech population? Pathol Oncol Res. 2009;15:733–40.PubMedCrossRef Coufal O, Pavlik T, Fabian P, Bori R, Boross G, Sejben I, et al. Predicting non-sentinel lymph node status after positive sentinel biopsy in breast cancer: what model performs the best in a Czech population? Pathol Oncol Res. 2009;15:733–40.PubMedCrossRef
40.
Zurück zum Zitat Poirier E, Sideris L, Dube P, Drolet P, Meterissian SH. Analysis of clinical applicability of the breast cancer nomogram for positive sentinel lymph node: the canadian experience. Ann Surg Oncol. 2008;15(9):2562–7.PubMedCrossRef Poirier E, Sideris L, Dube P, Drolet P, Meterissian SH. Analysis of clinical applicability of the breast cancer nomogram for positive sentinel lymph node: the canadian experience. Ann Surg Oncol. 2008;15(9):2562–7.PubMedCrossRef
41.
Zurück zum Zitat Hwang RF, Krishnamurty S, Hunt KK, Mirza N, Ames FC, Feig B, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;190:543–50. Hwang RF, Krishnamurty S, Hunt KK, Mirza N, Ames FC, Feig B, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;190:543–50.
42.
Zurück zum Zitat Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91(2):113–9.PubMedCrossRef Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91(2):113–9.PubMedCrossRef
43.
Zurück zum Zitat Ahn SH, Kim HJ, Lee JW, Gong GY, Noh DY, Yang JH, et al. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. Breast Cancer Res Treat. 2011;130(2):507–11.PubMedCrossRef Ahn SH, Kim HJ, Lee JW, Gong GY, Noh DY, Yang JH, et al. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. Breast Cancer Res Treat. 2011;130(2):507–11.PubMedCrossRef
44.
Zurück zum Zitat Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be considered for incorporation into staging for breast cancer. Ann Surg Oncol. 2011;18(11):143–8.CrossRef Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be considered for incorporation into staging for breast cancer. Ann Surg Oncol. 2011;18(11):143–8.CrossRef
45.
Zurück zum Zitat Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, et al. Prognostic value of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian breast and colorectal cancer study group (ABCSG). Ann Surg Oncol. 2012;19(6):1808–17.PubMedCrossRef Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, et al. Prognostic value of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian breast and colorectal cancer study group (ABCSG). Ann Surg Oncol. 2012;19(6):1808–17.PubMedCrossRef
46.
Zurück zum Zitat Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703.PubMedCrossRef Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703.PubMedCrossRef
47.
Zurück zum Zitat Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106(1):4.PubMedCrossRef Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106(1):4.PubMedCrossRef
48.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927.PubMedCrossRef Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927.PubMedCrossRef
49.
Zurück zum Zitat Schem C, Jonat W, Ostertag H. German KISS study Group. Observation or standard axillary dissection after sentinel-node biopsy in breast cancer: final results from the German KISS study. J Clin Oncol. 2011;29(suppl 1):1012. Schem C, Jonat W, Ostertag H. German KISS study Group. Observation or standard axillary dissection after sentinel-node biopsy in breast cancer: final results from the German KISS study. J Clin Oncol. 2011;29(suppl 1):1012.
50.
Zurück zum Zitat Schlembach PJ, Buchholz TA, Ross MI, Kirsner SM, Salas GJ, Strom EA, et al. Relationship of sentinel and axillary level I–II nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001;51(3):671–8.PubMedCrossRef Schlembach PJ, Buchholz TA, Ross MI, Kirsner SM, Salas GJ, Strom EA, et al. Relationship of sentinel and axillary level I–II nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001;51(3):671–8.PubMedCrossRef
51.
Zurück zum Zitat Haffty BG, Hunt KK, Harris JR, Buchholz TA. Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol. 2011;29:1–3.CrossRef Haffty BG, Hunt KK, Harris JR, Buchholz TA. Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol. 2011;29:1–3.CrossRef
52.
Zurück zum Zitat Poortmans P. A bright future for radiotherapy in breast cancer. Radiother Oncol. 2007;82:243–6.PubMedCrossRef Poortmans P. A bright future for radiotherapy in breast cancer. Radiother Oncol. 2007;82:243–6.PubMedCrossRef
53.
Zurück zum Zitat Yarnold J, Bentzen SM, Coles C, Haviland J. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys. 2011;79(1):1–9.PubMedCrossRef Yarnold J, Bentzen SM, Coles C, Haviland J. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys. 2011;79(1):1–9.PubMedCrossRef
Metadaten
Titel
Consensus on the regional lymph nodes irradiation in breast cancer
verfasst von
E. Bayo
I. Herruzo
M. Arenas
M. Algara
Publikationsdatum
01.10.2013
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 10/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1027-z

Weitere Artikel der Ausgabe 10/2013

Clinical and Translational Oncology 10/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.